![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 29
Zeitschriftenartikel
Käsmann, Lukas; Eze, Chukwuka; Taugner, Julian; Nieto, Alexander; Hofstetter, Kerstin; Kröninger, Sophie; Guggenberger, Julian; Kenndoff, Saskia; Flörsch, Benedikt; Tufman, Amanda; Reinmuth, Niels; Duell, Thomas; Belka, Claus 
ORCID: https://orcid.org/0000-0002-1287-7825 und Manapov, Farkhad
(2023):
Concurrent/sequential versus sequential immune checkpoint inhibition in inoperable large stage III non-small cell lung cancer patients treated with chemoradiotherapy: a prospective observational study.
In: Journal of Cancer Research and Clinical Oncology, Bd. 149, Nr. 10: S. 7393-7403
[PDF, 1MB]
ORCID: https://orcid.org/0000-0002-1287-7825 und Manapov, Farkhad
(2023):
Concurrent/sequential versus sequential immune checkpoint inhibition in inoperable large stage III non-small cell lung cancer patients treated with chemoradiotherapy: a prospective observational study.
In: Journal of Cancer Research and Clinical Oncology, Bd. 149, Nr. 10: S. 7393-7403
[PDF, 1MB]
Holzgreve, Adrien ORCID: https://orcid.org/0000-0002-9566-8438; Taugner, Julian; Käsmann, Lukas; Müller, Philipp; Tufman, Amanda; Reinmuth, Niels; Li, Minglun; Winkelmann, Michael; Unterrainer, Lena M.; Nieto, Alexander E.; Bartenstein, Peter; Kunz, Wolfgang G. ORCID: https://orcid.org/0000-0002-5021-1952; Ricke, Jens; Belka, Claus ORCID: https://orcid.org/0000-0002-1287-7825; Eze, Chukwuka ORCID: https://orcid.org/0000-0003-3779-1398; Unterrainer, Marcus und Manapov, Farkhad
(2023):
Metabolic patterns on [18F]FDG PET/CT in patients with unresectable stage III NSCLC undergoing chemoradiotherapy ± durvalumab maintenance treatment.
In: European Journal of Nuclear Medicine and Molecular Imaging, Bd. 50, Nr. 8: S. 2466-2476
[PDF, 1MB]
ORCID: https://orcid.org/0000-0002-9566-8438; Taugner, Julian; Käsmann, Lukas; Müller, Philipp; Tufman, Amanda; Reinmuth, Niels; Li, Minglun; Winkelmann, Michael; Unterrainer, Lena M.; Nieto, Alexander E.; Bartenstein, Peter; Kunz, Wolfgang G. ORCID: https://orcid.org/0000-0002-5021-1952; Ricke, Jens; Belka, Claus ORCID: https://orcid.org/0000-0002-1287-7825; Eze, Chukwuka ORCID: https://orcid.org/0000-0003-3779-1398; Unterrainer, Marcus und Manapov, Farkhad
(2023):
Metabolic patterns on [18F]FDG PET/CT in patients with unresectable stage III NSCLC undergoing chemoradiotherapy ± durvalumab maintenance treatment.
In: European Journal of Nuclear Medicine and Molecular Imaging, Bd. 50, Nr. 8: S. 2466-2476
[PDF, 1MB]
Hofstetter, Kerstin; Taugner, Julian ORCID: https://orcid.org/0000-0003-1473-1202; Käsmann, Lukas; Mansoorian, Sina; Flörsch, Benedikt; Eze, Chukwuka; Tufman, Amanda; Reinmuth, Niels; Duell, Thomas; Belka, Claus ORCID: https://orcid.org/0000-0002-1287-7825 und Manapov, Farkhad
(2023):
First-site-metastasis pattern in patients with inoperable stage III NSCLC treated with concurrent chemoradiotherapy with or without immune check-point inhibition: a retrospective analysis.
In: Strahlentherapie und Onkologie [Forthcoming]
[PDF, 465kB]
ORCID: https://orcid.org/0000-0003-1473-1202; Käsmann, Lukas; Mansoorian, Sina; Flörsch, Benedikt; Eze, Chukwuka; Tufman, Amanda; Reinmuth, Niels; Duell, Thomas; Belka, Claus ORCID: https://orcid.org/0000-0002-1287-7825 und Manapov, Farkhad
(2023):
First-site-metastasis pattern in patients with inoperable stage III NSCLC treated with concurrent chemoradiotherapy with or without immune check-point inhibition: a retrospective analysis.
In: Strahlentherapie und Onkologie [Forthcoming]
[PDF, 465kB]
Taugner, Julian; Käsmann, Lukas; Karin, Monika; Eze, Chukwuka; Flörsch, Benedikt; Guggenberger, Julian; Li, Minglun; Tufman, Amanda; Reinmuth, Niels; Duell, Thomas; Belka, Claus und Manapov, Farkhad
(2022):
Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition.
In: Investigational new drugs, Bd. 40: S. 163-171
[PDF, 1MB]
Manapov, Farkhad; Eze, Chukwuka; Holzgreve, Adrien; Käsmann, Lukas; Nieto, Alexander; Taugner, Julian und Unterrainer, Marcus
(2022):
PET/CT for Target Delineation of Lung Cancer Before Radiation.
In: Seminars in Nuclear Medicine, Bd. 52, Nr. 6: S. 673-680
Käsmann, Lukas; Taugner, Julian; Eze, Chukwuka; Nieto, Alexander; Pelikan, Carolyn; Flörsch, Benedikt; Kenndoff, Saskia; Hofer, Thomas P.; Nössner, Elfriede; Schulz, Christian; Unterrainer, Marcus; Tufman, Amanda; Klauschen, Frederick; Jung, Andreas; Neumann, Jens; Kumbrink, Jorg; Reinmuth, Niels; Bartenstein, Peter; Belka, Claus und Manapov, Farkhad
(2022):
Prospective evaluation of immunological, molecular-genetic, image-based and microbial analyses to characterize tumor response and control in patients with unresectable stage III NSCLC treated with concurrent chemoradiotherapy followed by consolidation therapy with durvalumab (PRECISION): protocol for a prospective longitudinal biomarker study.
In: Translational Lung Cancer Research, Bd. 11, Nr. 7: S. 1503-1509
[PDF, 294kB]
Flörsch, Benedikt; Taugner, Julian; Käsmann, Lukas; Kenndoff, Saskia; Guggenberger, Julian; Tufman, Amanda; Reinmuth, Niels; Duell, Thomas; Belka, Claus; Eze, Chukwuka und Manapov, Farkhad
(2022):
Treatment patterns and prognosis of patients with inoperable stage III NSCLC after completion of concurrent chemoradiotherapy +/- immune checkpoint inhibition: a decade-long single-center historical analysis.
In: Journal of Cancer Research and Clinical Oncology, Bd. 149, Nr. 7: S. 3267-3276
[PDF, 1MB]
Eze, Chukwuka ORCID: https://orcid.org/0000-0003-3779-1398; Guggenberger, Julian Elias; Schmidt-Hegemann, Nina-Sophie; Kenndoff, Saskia; Taugner, Julian; Käsmann, Lukas; Schönecker, Stephan; Floersch, Benedikt; Li, Minglun; Belka, Claus und Manapov, Farkhad
(2022):
Pooled analysis on image-guided moderately hypofractionated thoracic irradiation in inoperable node-positive/recurrent patients with non-small cell lung cancer with poor prognostic factors and severely limited pulmonary function and reserve.
In: Cancer, Bd. 128, Nr. 12: S. 2358-2366
[PDF, 220kB]
ORCID: https://orcid.org/0000-0003-3779-1398; Guggenberger, Julian Elias; Schmidt-Hegemann, Nina-Sophie; Kenndoff, Saskia; Taugner, Julian; Käsmann, Lukas; Schönecker, Stephan; Floersch, Benedikt; Li, Minglun; Belka, Claus und Manapov, Farkhad
(2022):
Pooled analysis on image-guided moderately hypofractionated thoracic irradiation in inoperable node-positive/recurrent patients with non-small cell lung cancer with poor prognostic factors and severely limited pulmonary function and reserve.
In: Cancer, Bd. 128, Nr. 12: S. 2358-2366
[PDF, 220kB]
Taugner, Julian; Käsmann, Lukas; Eze, Chukwuka; Rühle, Alexander; Tufman, Amanda; Reinmuth, Niels; Duell, Thomas; Belka, Claus ORCID: https://orcid.org/0000-0002-1287-7825 und Manapov, Farkhad
(2021):
Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients.
In: Investigational new drugs, Bd. 39: S. 1189-1196
[PDF, 586kB]
ORCID: https://orcid.org/0000-0002-1287-7825 und Manapov, Farkhad
(2021):
Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients.
In: Investigational new drugs, Bd. 39: S. 1189-1196
[PDF, 586kB]
Unterrainer, Marcus; Taugner, Julian; Kasmann, Lukas; Tufman, Amanda; Reinmuth, Niels; Li, Minglun; Mittlmeier, Lena M.; Bartenstein, Peter; Kunz, Wolfgang G.; Ricke, Jens; Belka, Claus; Eze, Chukwuka und Manapov, Farkhad
(2021):
Differential role of residual metabolic tumor volume in inoperable stage III NSCLC after chemoradiotherapy +/- immune checkpoint inhibition.
In: European Journal of Nuclear Medicine and Molecular Imaging, Bd. 49, Nr. 4: S. 1407-1416
Taugner, Julian; Käsmann, Lukas; Karin, Monika; Eze, Chukwuka; Flörsch, Benedikt; Guggenberger, Julian; Li, Minglun; Tufman, Amanda; Reinmuth, Niels; Duell, Thomas; Belka, Claus und Manapov, Farkhad
(2021):
Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition.
In: Investigational New Drugs, Bd. 40, Nr. 1: S. 163-171
Taugner, Julian; Käsmann, Lukas; Eze, Chukwuka; Tufman, Amanda; Reinmuth, Niels; Duell, Thomas; Belka, Claus und Manapov, Farkhad
(2021):
Durvalumab after Chemoradiotherapy for PD-L1 Expressing Inoperable Stage III NSCLC Leads to Significant Improvement of Local-Regional Control and Overall Survival in the Real-World Setting.
In: Cancers, Bd. 13, Nr. 7, 1613
Unterrainer, Marcus; Taugner, Julian; Käsmann, Lukas; Tufman, Amanda; Reinmuth, Niels; Li, Minglun; Mittlmeier, Lena M.; Bartenstein, Peter; Kunz, Wolfgang G.; Ricke, Jens; Belka, Claus; Eze, Chukwuka und Manapov, Farkhad
(2021):
Differential role of residual metabolic tumor volume in inoperable stage III NSCLC after chemoradiotherapy ± immune checkpoint inhibition.
In: European journal of nuclear medicine and molecular imaging
[PDF, 848kB]
Kauffmann-Guerrero, Diego; Taugner, Julian; Eze, Chukwuka; Kaesmann, Lukas; Li, Minglun; Tufman, Amanda und Manapov, Farkhad
(2021):
Clinical Management and Outcome of Grade III Pneumonitis after Chemoradioimmunotherapy for Inoperable Stage III Non-Small Cell Lung Cancer-A Prospective Longitudinal Assessment.
In: Diagnostics, Bd. 11, Nr. 11, 1968
Schnoeller, Leon; Kaesmann, Lukas; Taugner, Julian; Abdo, Reem; Eze, Chukwuka und Manapov, Farkhad
(2021):
Prognostic Role of Lung Immune Scores for Prediction of Survival in Limited-stage Small Cell Lung Cancer.
In: In Vivo, Bd. 35, Nr. 2: S. 929-935
Taugner, Julian; Kaesmann, Lukas; Eze, Chukwuka; Ruehle, Alexander; Tufman, Amanda; Reinmuth, Niels; Duell, Thomas; Belka, Claus und Manapov, Farkhad
(2021):
Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients.
In: Investigational New Drugs, Bd. 39, Nr. 4: S. 1189-1196
Kaesmann, Lukas; Eze, Chukwuka; Taugner, Julian; Roengvoraphoj, Olarn; Belka, Claus und Manapov, Farkhad
(2020):
Implementation of durvalumab maintenance treatment after concurrent chemoradiotherapy in inoperable stage III non-small cell lung cancer (NSCLC)-a German radiation oncology survey.
In: Translational Lung Cancer Research, Bd. 9, Nr. 2: S. 288-293
Kaesmann, Lukas; Abdo, Reem; Eze, Chukwuka; Dantes, Maurice; Taugner, Julian; Gennen, Kathrin; Roengvoraphoj, Olarn; Rades, Dirk; Belka, Claus und Manapov, Farkhad
(2020):
External Validation of a Survival Score for Limited-Stage Small Cell Lung Cancer Patients Treated with Chemoradiotherapy.
In: Lung, Bd. 198, Nr. 1: S. 201-206
Gennen, Kathrin; Kaesmann, Lukas; Taugner, Julian; Eze, Chukwuka; Karin, Monika; Roengvoraphoj, Olarn; Neumann, Jens; Tufman, Amanda; Orth, Michael; Reu, Simone; Belka, Claus und Manapov, Farkhad
(2020):
Prognostic value of PD-L1 expression on tumor cells combined with CD8+TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
In: Radiation Oncology, Bd. 15, Nr. 1, 5
Kaesmann, Lukas; Eze, Chukwuka; Taugner, Julian; Roengvoraphoj, Olarn; Dantes, Maurice; Schmidt-Hegemann, Nina-Sophie; Schiopu, Sanziana; Belka, Claus und Manapov, Farkhad
(2020):
Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy.
In: Radiation Oncology, Bd. 15, Nr. 1, 167
Karin, Monika; Taugner, Julian; Kaesmann, Lukas; Eze, Chukwuka; Roengvoraphoj, Olarn; Tufman, Amanda; Belka, Claus und Manapov, Farkhad
(2020):
Association of Planning Target Volume with Patient Outcome in Inoperable Stage III NSCLC Treated with Chemoradiotherapy: A Comprehensive Single-Center Analysis.
In: Cancers, Bd. 12, Nr. 10, 3035
Hoffmann, Michael; Reitz, Daniel; Taugner, Julian; Roengvoraphoj, Olarn; Kaesmann, Lukas; Eze, Chukwuka; Karin, Monika; Belka, Claus und Manapov, Farkhad
(2020):
Blood Parameters Demonstrating a Significant Survival Impact in Patients With Locally Advanced NSCLC Undergoing Definitive Chemoradiotherapy.
In: Anticancer Research, Bd. 40, Nr. 4: S. 2319-2322
Roengvoraphoj, Olarn; Kaesmann, Lukas; Eze, Chukwuka; Taugner, Julian; Gjika, Arteda; Tufman, Amanda; Hadi, Indrawati; Li, Minglun; Mille, Erik; Gennen, Kathrin; Belka, Claus und Manapov, Farkhad
(2020):
Maximum standardized uptake value of primary tumor (SUVmax_PT) and horizontal range between two most distant PET-positive lymph nodes predict patient outcome in inoperable stage III NSCLC patients after chemoradiotherapy.
In: Translational Lung Cancer Research, Bd. 9, Nr. 3: S. 541-548
Taugner, Julian; Eze, Chukwuka; Kaesmann, Lukas; Roengvoraphoj, Olarn; Gennen, Kathrin; Karin, Monika; Petrukhnov, Oleg; Tufman, Amanda; Belka, Claus und Manapov, Farkhad
(2020):
Pattern-of-failure and salvage treatment analysis after chemoradiotherapy for inoperable stage III non-small cell lung cancer.
In: Radiation Oncology, Bd. 15, Nr. 1, 148
Kaesmann, Lukas; Taugner, Julian; Eze, Chukwuka; Roengvoraphoj, Olarn; Dantes, Maurice; Gennen, Kathrin; Karin, Monika; Petrukhnov, Oleg; Tufman, Amanda; Belka, Claus und Manapov, Farkhad
(2019):
Performance Status and Its Changes Predict Outcome for Patients With Inoperable Stage III NSCLC Undergoing Multimodal Treatment.
In: Anticancer Research, Bd. 39, Nr. 9: S. 5077-5081
Eze, Chukwuka; Taugner, Julian; Roengvoraphoj, Olarn; Schmidt-Hegemann, Nina-Sophie; Kaesmann, Lukas; Wijaya, Cherylina; Belka, Claus und Manapov, Farkhad
(2019):
Initial report on feasibility of PET/CT-based image-guided moderate hypofractionated thoracic irradiation in node-positive non-small cell lung Cancer patients with poor prognostic factors and strongly diminished lung function: a retrospective analysis.
In: Radiation Oncology, Bd. 14, Nr. 1, 163
Taugner, Julian; Kaesmann, Lukas; Eze, Chukwuka; Dantes, Maurice; Roengvoraphoj, Olarn; Gennen, Kathrin; Karin, Monika; Petruknov, Oleg; Tufman, Amanda; Belka, Claus und Manapov, Farkhad
(2019):
Survival score to characterize prognosis in inoperable stage III NSCLC after chemoradiotherapy.
In: Translational Lung Cancer Research, Bd. 8, Nr. 5: S. 593-604
Roengvoraphoj, Olarn; Wijaya, Cherylina; Eze, Chukwuka; Li, Minglun; Dantes, Maurice; Taugner, Julian; Tufman, Amanda; Huber, Rudolf Maria; Belka, Claus und Manapov, Farkhad
(2018):
Analysis of primary tumor metabolic volume during chemoradiotherapy in locally advanced non-small cell lung cancer.
In: Strahlentherapie und Onkologie, Bd. 194, Nr. 2: S. 107-115
Roengvoraphoj, Olarn; Eze, Chukwuka; Wijaya, Cherylina; Dantes, Maurice; Taugner, Julian; Tufman, Amanda; Huber, Rudolf Maria; Bartenstein, Peter; Belka, Claus und Manapov, Farkhad
(2018):
How much primary tumor metabolic volume reduction is required to improve outcome in stage III NSCLC after chemoradiotherapy? A single-centre experience.
In: European Journal of Nuclear Medicine and Molecular Imaging, Bd. 45, Nr. 12: S. 2103-2109